Gorham-stout syndrome: A monocyte-mediated cytokine propelled disease

Journal of Bone and Mineral Research

Volumn 21, Issue 2, 2006, Pages 207-218

  Colucci, Silvia ^a   Taraboletti, Giulia ^b   Primo, Luca ^c   Viale, Andrea ^c   Roca, Cristina ^c   Valdembri, Donatella ^c   Geuna, Massimo ^d   Pagano, Marco ^c   Grano, Maria ^a   Pogrel, Anthony M ^e   Harris, Adrian L ^f   Athanasou, Nicholas N ^g   Mantovani, Alberto ^h   Zallone, Alberta ^a   Bussolino, Federico ^c,i  

^a UNIVERSITY OF BARI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Angiogenesis; Cytokine; Gorham Stout disease; Monocyte; Osteoclast

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MATRIGEL; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DISEASE; CELL ADHESION; CELL CULTURE; CELL FUNCTION; CELL INVASION; CELL ISOLATION; CELL LINEAGE; CELL MATURATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CELL TYPE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GORHAM STOUT SYNDROME; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VIVO STUDY; LYMPH VESSEL; LYMPHANGIOMATOSIS; MACROPHAGE; MONOCYTE; NONHUMAN; NUDE MOUSE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN SECRETION;

ANIMALS; ANTIGENS, SURFACE; BONE AND BONES; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; MICE; MICE, INBRED STRAINS; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS; OSTEOLYSIS, ESSENTIAL; SYNDROME;

EID: 33144465966     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.051019     Document Type: Article

References (57)

1. Florchinger A, Bottger E, Claass-Bottger F, Georgi M, Harms J 1998 Gorham Stout syndrome of the spine: Case report and review of the literature. Rofo-Fortschr Geb Rontgenstr Neuen Bildgeb Verfhar 168:68-76.
2. Choma ND, Biscotti CV, Bauer TW, Mehta AC, Licata AA 1987 Gorham's syndrome: A case report and review of the literature. Am J Med 83:1151-1156.
3. Dunbar SF, Rosenberg A, Mankin H, Rosenthal D, Suit HD, Phil D 1993 Gorham's massive osteolysis: The role of radiation therapy and a review of the literature. Int J Radiat Oncol Biol Phys 26:491-497.
4. Gorham LW, Wright AW, Schultz HH, Maxon FC 1954 Disappearing bone: A rare form of massive osteolysis. Am J Med 17:674-682.
5. Tie MLH, Poland GA, Rosenow EC 1994 Chylothorax in Gorham's syndrome. A common complication of a rare disease. Chest 105:208-213.
6. Foult H, Goupille P, Aesch B, Valat JP, Burdin P, Jan M 1995 Massive osteolysis of the cervical spine. A case report. Spine 20:1636-1639.
7. Thompson JS, Schurman DJ 1974 Massive osteolysis. Case report and review of literature. Clin Orthop 103:206-211.
8. Dickson GR, Hamilton A, Hayes D, Carr KE, Davis R, Mollan RA 1990 An investigation of vanishing bone disease. Bone 11:201-210.
9. Kery L, Wouters HW 1970 Massive osteolysis. Report of two cases. J Bone Joint Surg Br 52:452-459.
10. Cannon SR 1986 Massive osteolysis: A review of seven cases. J. Bone Joint Surg Br 68:24-28.
11. Moller G, Priemel M, Amling M, Werner M, Kuhlmey AS, Delling G 1999 The Gorham-Stout syndrome (Gorham's massive osteolysis). A report of six cases with histopathological findings. J Bone Joint Surg Br 81:501-506.
12. Hirayama T, Sabokbar A, Itonaga I, Watt-Smith S, Athanasou NA 2001 Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J Pathol 195:624-630.
13. Devlin RD, Bone HG III, Roodman A 1996 Interleukin-6: A potent mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab 81:1893-1897.
14. Hardegger F, Simpson LA, Segmueller G 1985 The syndrome of idiopathic osteolysis. Classification, review, and case report. J Bone Joint Surg Br 67:89-93.
15. Schoenau E, Rauch F 2002 Fibrous dysplasia. Horm Res 57(Suppl 2):79-82.
16. Roodman GD, Windle JJ 2005 Paget disease of bone. J Clin Invest 115:200-208.
17. Lymboussaki A, Partanen TA, Olofsson B, Thomas-Crusells J, Fletcher CD, de Waal RM, Kaipainen A, Alitalo K 1998 Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 153:395-403.
18. Grano M, Colucci S, De Bellis M, Zigrino P, Argentino L, Zambonin G, Serra M, Scotlandi K, Teti A, Zambonin Zallone A 1994 New model for bone resorption study in vitro: Uman osteoclast-like cells from giant cell tumor of bone. J Bone Miner Res. 7:1013-1020.
19. Bussolino F, Di Renzo MF, Ziehe M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM 1992 Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629-641.
20. Mitola S, Sozzani S, Luini W, Arese M, Borstatti A, Weich HA, Bussolino F 1997 Tat-HIV-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood 90:1365-1372.
21. Blair HC, Kahan AJ, Crouch EC, Jeffrey JJ, Teitelbaum SL 1986 Isolated osteoclasts resorb the organic and inorganic components of bone. J Cell Biol 102:1164-1172.
22. Poli G, Wang JM, Ruco L, Rossini S, Biondi A, Mantovani A, Uccini S 1993 Expression and modulation of a mononuclear phagocyte differentiation antigen (PAM-1) during in vitro maturation of peripheral blood monocytes. Int J Clin Lab Res 23:83-87.
23. Fisher KL, Pogrel MA 1990 Gorham's syndrome (massive osteolysis): A case report. J Oral Maxillofac Surg 48:1222-1225.
24. Hagberg H, Lamberg K, Astrom G 1997 Alpha-2b interferon and oral clodronate for Gorham's disease. Lancet 350:1822-1823.
25. Soldi R, Mitola S, Strasly S, Defilippi P, Tarone G, Bussolino F 1999 Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18:734-740.
26. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson WG 1994 Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: Inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 8:1237-1244.
27. Mitola S, Strasly M, Prato M, Ghia P, Bussolino F 2003 IL-12 regulates an endothelial cell-lymphocyte network: Effect on metalloproteinase-9 production. J Immunol 171:3725-3733.
28. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, Bussolino F 1996 The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 2:1371-1375.
29. Aviv RI, McHugh K, Hunt J 2001 Angiomatosis of bone and soft tissue: A spectrum of disease from diffuse lymphangiomatosis to vanishing bone disease in young patients. Clin Radiol 56:184-190.
30. Giachelli CM, Steitz S 2000 Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biol 19:615-622.
31. Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:1504-1508.
32. Suda T, Nakamura I, Jimi E, Takahashi N 1997 Regulation of osteoclast function. J Bone Miner Res 12:869-879.
33. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM 1992 Interleukin-8 (IL-8) as a macrophage-derived mediator of angiogenesis. Science 258:1978-1982.
34. Heiden G, Kindbloom LG, Nielsen JM 1977 Disappearing bone disease: A clinical and histological study. J Bone Joint Surg Am 59:57-61.
35. Poirier H 1968 Massive osteolysis of the humerus treated by resection and prosthetic replacement. J Bone Joint Surg Br 50:158-160.
36. Kawasaki K, Ito T, Tsuchiya T, Takahashi H 2003 Is angiomatosis an intrinsic pathohistological feature of massive osteolysis? Report of an utopsy and a review of the literature. Virchows Arch 442:400-406.
37. Athanasou NA, Quinn J 1990 Immunophenotypic differences between osteoclasts and macrophage polykaryons: Immunohistological distinctions and implications for osteoclast ontogeny and function. J Clin Pathol 43:997-1003.
38. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
39. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda M, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor α stimulates osteoclast differentiation by a mechanisms independent of ODF/RANKL-RANK interaction. J Exp Med 191:275-285.
40. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A 2000 Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275:4858-4864.
41. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S 1990 The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444.
42. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T 1999 Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741-1754.
43. Muguruma Y, Lee MY 1998 Isolation and characterization of murine clonogenic osteoclast progenitors by cell surface phenotype analysis. Blood 91:1272-1279.
44. Takeshita S, Kaji K, Kudo A 2000 Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 15:1477-1488.
45. Ohsaki Y, Takahashi S, Scarcez T, Demulder A, Nishihara T, Williams R, Roodman GD 1992 Evidence for an autocrine/paracrine role of interleukin-6 in bone resorption by giant cells from tumors of bone. Endocrinology 131:2229-2234.
46. O'Keefe RJ, Teot LA, Singh D, Puzas JE, Rosier NM, Hicks DG 1997 Osteoclasts constitutively express regulators of bone resorption: An immunohistochemical and in situ hybridation study. Lab Invest 76:457-465.
47. Ferrara N, Gerber HP, LeCouter J 2003 The biology of VEGF and its receptors. Nat Med 9:669-676.
48. Werb Z 1997 ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91:439-442.
49. Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81.
50. Coussens LZ, Werb Z 2002 Inflammation and cancer. Nature 420:860-867.
51. Ensoli B, Sturzl M 1998 Kaposi's Sarcoma: A result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev 9:63-83.
52. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY 2003 Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22:1517-1527.
53. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y 2000 Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161-164.
54. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342.
55. Chen YH, Shiao RT, Labayog JM, Modi S, Lavelle D 1997 Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma. Leuk Lymphoma 27:11-23.
56. Giraudo EIM, Hanahan D 2004 An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623-633.
57. Green JR 2004 Bisphosphonates: Preclinical review. Oncologist 9(Suppl 4):3-13.